Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

200111,443 citationsJournal Articlebronze Open Access

Authors

Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.

Good health and well-being

Published in: New England Journal of Medicine

Volume 344, Issue 11, pp. 783-792

Field-Weighted Citation Impact: 155.17